Register Login
Register to leave comments
  • News bot May 5, 2026, 12:09 p.m.

    📋 COGENT BIOSCIENCES, INC. (COGT) - Financial Results

    Filing Date: 2026-05-05

    Accepted: 2026-05-05 08:08:36

    Event Type: Financial Results

    Event Details:

    COGENT BIOSCIENCES, INC. (COGT) Reports the reporting period Financial Results COGENT BIOSCIENCES, INC. (COGT) announced its financial results for the period ending the reporting period. Key Financial Highlights:
    • Revenue: Not disclosed
    • Net Income: Not disclosed
    • EPS: Not disclosed
    • Cash and equivalents: 866378
      • Planning for dual launches of bezuclastinib in Systemic Mastocytosis and Gastrointestinal Stromal Tumors (GIST)
      • Pivotal data from Phase 3 PEAK trial in GIST patients selected for oral presentation at 2026 ASCO annual meeting
      • 4 million in cash, sufficient to fund operations into 2028 WALTHAM, Mass. and BOULDER, Colo., May 5, 2026 – Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today provided a business update and announced financial results for the first quarter ended March 31,
        • targeting mutations in ErbB2, PI3Kα, KRAS and JAK2. Cogent Biosciences is based in Waltham, MA and Boulder, CO. Visit our website for more information at www.cogentbio.com. Follow Cogent Biosciences on social media: X (formerly known as Twitter) and LinkedIn. Information that may be important to investors will be routinely posted on our website and X. Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995

    📊 Key Financial Metrics (Year-over-Year Comparison):

    Metric 2026 2025 Change ($) Change (%)
    Operating Expenses Loss From Operations 103.61K 74.93K $28.67K +38.27%
    Other Income Interest Income 7.61K 2.95K $4.66K +157.72%
    Other Income Total Other Income Expense 140.00 5.00 $135.00 +2700.00%
    Other Income Net Loss 97.35K 71.99K $25.37K +35.24%
    Cash Equivalents Marketable Securities 866.38K 900.76K $-34.39K -3.82%
    Loss from Operations 103.61K 74.93K $28.67K +38.27%
    Interest Income 7.61K 2.95K $4.66K +157.72%
    Other Income, Net 6.25K 2.95K $3.31K +112.25%
    Net Loss 97.35K 71.99K $25.37K +35.24%
    Cash and Marketable Securities 866.38K 900.76K $-34.39K -3.82%

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: COGENT BIOSCIENCES, INC.
    • Ticker Symbol: COGT

Search

News categories